Incyte (NASDAQ: INCY)
Incyte Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Incyte Company Info
Incyte isn't the only drugmaker with a JAK inhibitor, but Jakafi's differentiation as a JAK1 and JAK2 inhibitor has helped the company stay on top of the treatment paradigm for myelofibrosis.
News & Analysis
Incyte Surpasses Q3 Revenue Estimates
Incyte delivered robust third-quarter revenue growth, surpassing expectations, despite increased operational costs.
3 Stocks the World's Smartest Investors Are Buying Hand Over Fist Right Now
Billionaire investors are backing up their trucks and loading up on these stocks.
2 Under-the-Radar Biotech Stocks to Buy in 2022
Don't overlook these two promising companies.
Is the PD-(L)1 Party Over After Incyte's FDA Rejection?
There's definitely already a crowded market for PD-1 and PD-L1 immunotherapies.
2 Stocks Under $100 You Can Buy and Hold Forever
Drugmakers can be excellent long-term holdings.
This Underperforming Biotech Is Ready to Beat the Market
Incyte is betting bigger on ruxolitinib to bring back growth.
What's Behind Incyte's Better-Than-Expected Q4 Earnings
Several products contributed to the biotech's solid Q4 growth.
The Biggest Drug Competition in 2021 (Hint: It Isn't COVID Vaccines)
Investors should take notice of this four-way competition.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.